Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma (RPRX) navigates growth via strategic investments and shareholder returns. Recent collaborations, bond monetization, and dividend hikes underscore its approach.
Royalty Pharma (RPRX) navigates the biopharmaceutical landscape through strategic capital allocation, R&D collaborations, and shareholder value initiatives. Recent Q4 results and the Biogen collaboration underscore its growth commitment.
Royalty Pharma (RPRX) Q4 2024 results showcase strong financials and strategic investments, including a Biogen collaboration and dividend increase. A deep dive into growth and outlook.
Royalty Pharma (RPRX) demonstrates strong Q4 2024 performance, strategic investments, and commitment to shareholder value. Analyst consensus points to a positive outlook.